Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity ; volume:33 ; number:1 ; day:22 ; month:9 ; year:2013 ; pages:39-47 ; date:1.2014
Clinical rheumatology ; 33, Heft 1 (22.9.2013), 39-47, 1.2014
- Urheber
-
Takahashi, Nobunori
Kojima, Toshihisa
Kaneko, Atsushi
Kida, Daihei
Hirano, Yuji
Fujibayashi, Takayoshi
Yabe, Yuichiro
Takagi, Hideki
Oguchi, Takeshi
Miyake, Hiroyuki
Kato, Takefumi
Fukaya, Naoki
Ishikawa, Hisato
Hayashi, Masatoshi
Tsuboi, Seiji
Kanayama, Yasuhide
Kato, Daizo
Funahashi, Koji
Matsubara, Hiroyuki
Hattori, Yosuke
Hanabayashi, Masahiro
Hirabara, Shinya
Terabe, Kenya
Yoshioka, Yutaka
Ishiguro, Naoki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-013-2392-2
- URN
-
urn:nbn:de:101:1-2019101400352971706306
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Takahashi, Nobunori
- Kojima, Toshihisa
- Kaneko, Atsushi
- Kida, Daihei
- Hirano, Yuji
- Fujibayashi, Takayoshi
- Yabe, Yuichiro
- Takagi, Hideki
- Oguchi, Takeshi
- Miyake, Hiroyuki
- Kato, Takefumi
- Fukaya, Naoki
- Ishikawa, Hisato
- Hayashi, Masatoshi
- Tsuboi, Seiji
- Kanayama, Yasuhide
- Kato, Daizo
- Funahashi, Koji
- Matsubara, Hiroyuki
- Hattori, Yosuke
- Hanabayashi, Masahiro
- Hirabara, Shinya
- Terabe, Kenya
- Yoshioka, Yutaka
- Ishiguro, Naoki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Tocilizumab: A Review in Rheumatoid Arthritis
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Tocilizumab: A Review in Rheumatoid Arthritis
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Tocilizumab: A Review in Rheumatoid Arthritis
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study